Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Trelegy Ellipta (fluticasone): where help paying exists, what Medicare negotiated and what pharmacies pay
1 assistance program lists fluticasone, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $175 on January 1, 2027. The FDA's enforcement reports name this drug's packages in 2 recall entries. ClinicalTrials.gov lists 3 recruiting trials that name fluticasone.
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00173-0887-10 | TRELEGY ELLIPTA 1X30D TRD100/62.5/25MCG PK/CA | EA | n/a | $2.93 | $11.15 | - |
| 00173-0887-14 | TRELEGY ELLIPTA 1X14D INST100/62.5/25MCG PK/CA | EA | n/a | $2.93 | $11.09 | - |
| 00173-0893-10 | TRELEGY ELLIPTA 200/62.5/25MCG 1X30D TRADE PACK | EA | n/a | $2.93 | $11.15 | - |
| 00173-0893-14 | TRELEGY ELLIPTA 200/62.5/25MCG 1X14D INST PACK | EA | n/a | $2.93 | $11.20 | - |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA209482 | Trelegy Ellipta 1x14d Inst100/62.5/25mcg Pk/ca, Trelegy Ellipta 1x30d Trd100/62.5/25mcg Pk/ca, Trelegy Ellipta 200/62.5/25mcg 1x14d Inst Pack, Trelegy Ellipta 200/62.5/25mcg 1x30d Trade Pack | April 11, 2031 | none listed | April 11, 2031 | patent 8746242 with its pediatric extension; 15 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Trelegy Ellipta of $5.29 billion in 2024, across 6,250,872 claims and 1,268,914 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $5.29 billion | 6,250,872 | 1,268,914 | $847 |
| 2023 | $4.46 billion | 5,009,961 | 1,050,583 | $889 |
| 2022 | $3.34 billion | 3,926,585 | 834,046 | $851 |
| 2021 | $2.39 billion | 2,964,362 | 645,157 | $807 |
| 2020 | $1.49 billion | 1,987,542 | 419,392 | $749 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 1 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 98 | $19,221 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (1 state and package figure is marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 118 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list fluticasone. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- GSK Patient Assistance Program manufacturer
Income at or below $47,880 for one person (300% FPL)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated June 2, 2023 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Trelegy Ellipta by its NDC: 2 entries, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| June 2, 2021D-0481-2021 | Class II | Terminated | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | 4 |
| June 2, 2021D-0482-2021 | Class II | Terminated | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | 4 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 3 interventional trials that name fluticasone and are recruiting, and 2 more not yet recruiting. By phase: Phase 4: 1, Phase 2: 1, Phase 3: 1. The 3 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07192016 | 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationChronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Western University, Canada | July 31, 2026 | Canada |
| NCT07282886 | VENTURI (VENTilation Using Respiratory Imaging)Asthma | Phase 2 | University of Alabama at Birmingham | April 13, 2026 | United States |
| NCT06474039 | The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPDCOPD | Phase 3 | Mahidol University | May 6, 2025 | Thailand |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Trelegy Ellipta?
The CMS file publishes $175 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Trelegy Ellipta?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Trelegy Ellipta arrive?
For Trelegy Ellipta, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA209482, April 11, 2031. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Trelegy Ellipta?
ClinicalTrials.gov lists 3 recruiting interventional trials that name fluticasone (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Trelegy Ellipta?
CMS's Medicare Part D spending dataset reports gross spending on Trelegy Ellipta of $5.29 billion in 2024, across 6,250,872 claims and 1,268,914 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/trelegy-ellipta.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.